Absci to Participate in Upcoming Investor Conferences Discussing AI-Driven Therapeutics

Absci Corporation, a clinical-stage biopharmaceutical company leveraging generative AI to advance therapeutics, will participate in two upcoming investor conferences. The events will feature fireside chats that provide insight into the company’s cutting-edge approach and recent developments.

On September 15, 2026, Absci will join the H.C. Wainwright 28th Annual Global Investment Conference in New York, New York. At 3:30 p.m. Eastern Time (12:30 p.m. Pacific Time), an executive from the company will engage in a fireside chat, offering a detailed look at Absci’s Integrated Drug Creation™ platform and its innovative use of AI in drug discovery.

A day later, on September 16, Absci will participate in the Morgan Stanley 24th Annual Global Healthcare Conference, also held in New York. The fireside chat is scheduled for 7:45 a.m. Eastern Time (4:45 a.m. Pacific Time) and will cover similar topics, providing an in-depth discussion on Absci’s technology and its potential in the biopharmaceutical industry.

Absci Corporation is at the forefront of drug discovery, utilizing advanced AI models and synthetic biology to create innovative biologics. The company’s Integrated Drug Creation™ platform combines AI with wet lab validation, creating a continuous feedback loop that accelerates the development of therapeutic targets. This approach has enabled Absci to advance its pipeline, including ABS-201™, a potential breakthrough in hair regrowth and a leading candidate for endometriosis treatment.

Based in Vancouver, Washington, Absci operates AI Research Labs in New York City and Serbia, and an Innovation Center in Switzerland. The company is collaborating with leading pharmaceutical, biotech, tech, and academic partners to drive innovation and develop next-generation therapeutics.